Inflammatory Bowel Disease Treatment Market Size Set for Rapid Expansion, Valued at USD 34.5 Billion Revenue by 2031

June 20, 2025 02:56 AM AEST | By EIN Presswire
 Inflammatory Bowel Disease Treatment Market Size Set for Rapid Expansion, Valued at USD 34.5 Billion Revenue by 2031
Image source: EIN Presswire

Rise in prevalence of ulcerative colitis and Crohn’s disease, growing awareness of the disease across the world, drives the growth of the market PORTLAND, OR, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- Allied Market Research has published a study report with the title Inflammatory Bowel Disease Treatment Market Size accounted for 𝐔𝐒𝐃 𝟐𝟏.𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟏, and it is estimated to surpass around 𝐔𝐒𝐃 𝟑𝟒.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟏, registering a 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟏% from 2022 to 2031.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/4318

𝑹𝒊𝒔𝒆 𝒊𝒏 𝒕𝒉𝒆 𝒑𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆 𝒐𝒇 𝒖𝒍𝒄𝒆𝒓𝒂𝒕𝒊𝒗𝒆 𝒄𝒐𝒍𝒊𝒕𝒊𝒔 𝒂𝒏𝒅 𝑪𝒓𝒐𝒉𝒏’𝒔 𝒅𝒊𝒔𝒆𝒂𝒔𝒆, 𝒈𝒓𝒐𝒘𝒊𝒏𝒈 𝒂𝒘𝒂𝒓𝒆𝒏𝒆𝒔𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒅𝒊𝒔𝒆𝒂𝒔𝒆 𝒂𝒄𝒓𝒐𝒔𝒔 𝒕𝒉𝒆 𝒘𝒐𝒓𝒍𝒅, 𝒂𝒏 𝒊𝒏𝒄𝒓𝒆𝒂𝒔𝒆 𝒊𝒏 𝒕𝒉𝒆 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 𝒐𝒇 𝒏𝒆𝒘 𝒅𝒓𝒖𝒈𝒔, 𝒂𝒏𝒅 𝒊𝒏𝒄𝒓𝒆𝒂𝒔𝒆𝒅 𝒈𝒐𝒗𝒆𝒓𝒏𝒎𝒆𝒏𝒕 𝒔𝒖𝒑𝒑𝒐𝒓𝒕 𝒇𝒐𝒓 𝒕𝒉𝒆 𝒎𝒂𝒏𝒂𝒈𝒆𝒎𝒆𝒏𝒕 𝒐𝒇 𝒊𝒏𝒇𝒍𝒂𝒎𝒎𝒂𝒕𝒐𝒓𝒚 𝒃𝒐𝒘𝒆𝒍 𝒅𝒊𝒔𝒆𝒂𝒔𝒆 𝒅𝒓𝒊𝒗𝒆 𝒕𝒉𝒆 𝒈𝒓𝒐𝒘𝒕𝒉 𝒐𝒇 𝒕𝒉𝒆 𝒈𝒍𝒐𝒃𝒂𝒍 𝒊𝒏𝒇𝒍𝒂𝒎𝒎𝒂𝒕𝒐𝒓𝒚 𝒃𝒐𝒘𝒆𝒍 𝒅𝒊𝒔𝒆𝒂𝒔𝒆 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕 𝒎𝒂𝒓𝒌𝒆𝒕. 𝑩𝒂𝒔𝒆𝒅 𝒐𝒏 𝒕𝒚𝒑𝒆, 𝒕𝒉𝒆 𝑪𝒓𝒐𝒉𝒏’𝒔 𝒅𝒊𝒔𝒆𝒂𝒔𝒆 𝒔𝒆𝒈𝒎𝒆𝒏𝒕 𝒊𝒔 𝒍𝒊𝒌𝒆𝒍𝒚 𝒕𝒐 𝒎𝒂𝒊𝒏𝒕𝒂𝒊𝒏 𝒊𝒕𝒔 𝒅𝒐𝒎𝒊𝒏𝒂𝒏𝒄𝒆 𝒕𝒉𝒓𝒐𝒖𝒈𝒉 2031. 𝑹𝒆𝒈𝒊𝒐𝒏-𝒘𝒊𝒔𝒆, 𝑨𝒔𝒊𝒂-𝑷𝒂𝒄𝒊𝒇𝒊𝒄 𝒘𝒐𝒖𝒍𝒅 𝒆𝒙𝒉𝒊𝒃𝒊𝒕 𝒕𝒉𝒆 𝒇𝒂𝒔𝒕𝒆𝒔𝒕 𝑪𝑨𝑮𝑹 𝒅𝒖𝒓𝒊𝒏𝒈 𝒕𝒉𝒆 𝒇𝒐𝒓𝒆𝒄𝒂𝒔𝒕 𝒑𝒆𝒓𝒊𝒐𝒅.

𝐓𝐨𝐩 𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐁𝐨𝐰𝐞𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

• AbbVie Inc.
• Bristol Myers Squibb
• Celltrion Healthcare
• Eli-Lilly
• Johnson & Johnson Services Inc.
• Merck & Co, Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd.
• UCB S.A.

𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐁𝐨𝐰𝐞𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

By Type

• Ulcerative Colitis
• Crohn's Disease

By Drug Class

• TNF inhibitors
• Corticosteroids
• Aminosalicylates
• JAK inhibitors
• Anti-integrin
• IL inhibitors
• Others

By Distribution Channel

• Hospital Pharmacy
• Drug Store and Retail Pharmacy
• Online Pharmacy

Based on region, North America accounted for the largest share in 2021, contributing to more than two-fifths of the global inflammatory bowel disease treatment market, and is likely to dominate the market during the forecasted timeframe. However, Asia-Pacific is expected to exhibit the fastest CAGR of 6.6% during the forecast period. The research also analyzes the regions including Europe and LAMEA.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/4318

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inflammatory bowel disease drugs market analysis from 2021 to 2031 to identify the prevailing inflammatory bowel disease drugs market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the inflammatory bowel disease drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes an analysis of the regional as well as global inflammatory bowel disease drugs market trends, key players, market segments, application areas, and market growth strategies.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
[email protected]

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.